# A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

> **NCT02790125** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 66 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BMS-986166
- **DRUG:** Placebo matching BMS-986166

## Key facts

- **NCT ID:** NCT02790125
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-28
- **Primary completion:** 2017-11-07
- **Final completion:** 2017-11-07
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2017-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02790125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02790125, "A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02790125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*